ALung Technologies, Inc. announced that it has now treated more than 75 COVID-19 patients, and that it is experiencing increasing demand for the Hemolung® Respiratory Assist System (RAS) as a result of the current pandemic.
An immunotherapy startup that spun out of UPMC Enterprises, BlueSphere Bio, has raised $45 million, according to a filing with the U.S. Securities and Exchange Commission.
Capped by a recent investment from 3M Ventures and including previous investments by funds managed by affiliates of Apollo Global Management, Safeguard Scientifics, Summit Action, and UPMC Enterprises, this funding supports the rapid growth of Moxe’s network of connected payer and provider organizations.
The financing was led by RA Capital Management and included investors from Werewolf’s Series A including UPMC Enterprises, MPM Capital, Longwood Fund, and others.
HIT Consultant sat down with Mike McSherry, CEO and co-founder of Seattle-based digital prescription platform Xealth, to discuss digital health lessons learned in 2020 and what we can expect in 2021.
